Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of hepatitis A, pneumococcal, and rabies vaccination in immunocompromised adults
NL-OMON56421Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2018
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of Hepatitis A virus vaccine, Prevnar 13, 23-valent pneumococcal polysaccharide vaccine, Prevnar 20 and Rabies vaccine in hepatitis A (HAV), pneumococcal disease and rabies (2 arms), sponsored by Amsterdam University Medical Center. Started Aug 2018; status: recruiting.
02
Drugs
Hepatitis A virus vaccinePrevnar 1323-valent pneumococcal polysaccharide vaccinePrevnar 20Rabies vaccine
03
Conditions
hepatitis A (HAV)pneumococcal diseaserabies
Beyond the preview
Go deeper on NL-OMON56421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56421.